Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lucid Group Inc (LCID) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lucid Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Lucid Group Inc trades at $5.54 (market cap $2.17B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 18.4× Lucid Group Inc's market cap. Which is the better fit depends on your goals.
| ALNY | LCID | |
|---|---|---|
Market Cap | $39.89B | $2.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $31.30 |
52-Week Low | $278.09 | $4.70 |
Enterprise Value | $38.15B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lucid Group (LCID) trades at $5.55, down 4.8% on the day, reflecting persistent bearish technical signals and fundamental challenges. The company continues to report significant losses, with a net income margin of -239.81% and negative cash flow from operations of $2.93B in 2025. Recent news highlights shareholder dilution concerns and multiple class-action lawsuits, adding to investor uncertainty.
The outlook remains highly speculative with substantial execution and liquidity risks, though a consensus analyst price target of $11.75 suggests potential upside if the company can achieve scale and improve profitability. High cash burn and competitive pressures in the EV market present significant headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
